Mammoth Biosciences to Present Preclinical Data on MB-111 at the European Society of Gene & Cell Therapy 32nd Annual Congress

Oral presentation highlights safe, robust reduction in apoC-III and triglycerides by MB-111, paving the way to the clinic in 2026.

Mammoth Biosciences, Inc.: Mammoth Biosciences to Present Preclinical Data on MB-111 at the European Society of Gene & Cell Therapy 32nd Annual Congress

MB-111 is a potential first-in-class, single-dose in vivo CRISPR gene editing therapy for persistent chylomicronemia Oral presentation highlights safe, robust, and durable reduction of apoC-III ...